Cytokinetics CYTK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$206.03M-12.6% | -$183.03M+40.2% | -$306.18M-128% | -$134.37M+16.7% | -$161.38M-7.6% | ||
| $3.38M+18.1% | $2.86M+6.8% | $2.68M+17.2% | $2.29M-0.7% | $2.3M-3.5% | ||
| $30.39M-0.4% | $30.51M-0.6% | $30.7M+11.5% | $27.54M+16.9% | $23.55M-10.3% | ||
| -$10.94M-169% | $15.96M+342% | -$6.6M-203% | $6.4M+144% | -$14.64M-189% | ||
| $3.57M— | —— | —— | —— | $0— | ||
| $1.52M— | —— | $6.6M— | —— | -$4.58M— | ||
| -$6.21M-124% | $26.37M+246% | $7.62M-45.5% | $13.99M+197% | -$14.37M-243% | ||
| -$2.06M-149% | $4.2M+167% | -$6.28M-235% | $4.64M+1,133% | $376K-95.5% | ||
| -$3.95M-12.1% | -$3.53M-31.6% | -$2.68M-61.3% | -$1.66M-203% | $1.62M— | ||
| $41K— | —— | —— | -$51.03M— | $0-100% | ||
| -$145.46M-2.0% | -$142.65M-32.7% | -$107.51M+16.2% | -$128.24M+2.6% | -$131.62M-101% | ||
| $5.93M+5.1% | $5.64M-39.7% | $9.35M+126% | $4.15M-26.8% | $5.66M+339% | ||
| $106.52M-69.2% | $345.65M+3.0% | $335.45M+50.4% | $222.97M+40.1% | $159.11M+31.4% | ||
| $257.94M+3,224,125% | $8K+700% | $1K— | —— | $275.73M— | ||
| $145.49M— | —— | —— | $52.88M-50.1% | $105.96M— | ||
| —— | $182.37M0.0% | $182.37M0.0% | $182.37M0.0% | $182.37M— | ||
| $2.74M+0.5% | $2.72M+0.5% | $2.71M+0.5% | $2.7M+0.5% | $2.68M+0.4% | ||
| $11.35M-22.5% | $14.65M+111% | $6.94M-51.8% | $14.4M— | $0-100% | ||
| $0— | —— | —— | $2K-99.0% | $202K-16.9% | ||
| $841K-31.1% | $1.22M+69.6% | $720K+40.1% | $514K+3,854% | $13K-98.9% | ||
| $7.77M-93.0% | $110.71M-66.5% | $330.47M+321% | $78.53M+1,552% | $4.75M+99.4% | ||
| -$483K— | —— | —— | -$682K-153% | -$270K-192% | ||
| $7.32M— | —— | $152.03M— | —— | -$21.18M— | ||
| $1.59M-47.9% | $3.04M-68.4% | $9.62M+1,488% | $606K-93.7% | $9.65M+1,417% | ||
| $1.5M+66.7% | $900K+28.6% | $700K-76.7% | $3M+850% | -$400K-133% | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| $1.52M— | —— | $6.6M— | —— | -$4.58M— | ||
| $41K— | —— | —— | -$51.03M— | $0-100% | ||
| -$1.04M+75.4% | -$4.22M-96.4% | -$2.15M+7.4% | -$2.32M-8.4% | -$2.14M-5.8% | ||
| -$3.95M-12.1% | -$3.53M-31.6% | -$2.68M-61.3% | -$1.66M-203% | $1.62M— | ||
| -$2.06M-149% | $4.2M+167% | -$6.28M-235% | $4.64M+1,133% | $376K-95.5% | ||
| -$1.87M+39.1% | -$3.08M-14.1% | -$2.7M+33.1% | -$4.03M+34.7% | -$6.17M+19.8% | ||
| -$1.6M— | —— | -$2.8M+80.8% | -$14.6M-474% | $3.9M+185% | ||
| $18.82M+17.2% | $16.06M+7.1% | $15M+13.5% | $13.21M-6.4% | $14.1M+3.1% | ||
| $1.59M-1.6% | $1.61M+9.4% | $1.47M+10.2% | $1.34M+8.6% | $1.23M+5.9% | ||
| $8.46M-0.2% | $8.47M+50.0% | $5.65M+6.0% | $5.33M+54.4% | $3.45M-2.2% | ||
| $61K+663% | $8K+700% | $1K-93.8% | $16K— | $0-100% | ||
| $257.94M-7.9% | $280.09M+2.3% | $273.83M-0.1% | $274M-0.6% | $275.73M+18.2% | ||
| $0— | —— | —— | $2K-99.0% | $202K-16.9% | ||
| —— | $43.75M0.0% | $43.75M0.0% | $43.75M0.0% | $43.75M-12.5% | ||
| —— | $0— | $0— | —— | —— | ||
| $11.35M-22.5% | $14.65M+111% | $6.94M+2.8% | $6.75M-11.8% | $7.65M+18.1% | ||
| $4.19M+645% | $562K— | —— | $1.34M-10.6% | $1.49M-48.2% | ||
| $170K— | —— | $2.93M— | —— | $3.5M— | ||
| -$151.39M-2.1% | -$148.3M-26.9% | -$116.86M+11.7% | -$132.38M+3.6% | -$137.28M-105% | ||
| -$151.39M-2.1% | -$148.3M-26.9% | -$116.86M+11.7% | -$132.38M+3.6% | -$137.28M-105% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytokinetics generate?
- Cytokinetics (CYTK) generated -$523.8M in operating cash flow over the trailing twelve months.
- What is Cytokinetics's free cash flow?
- After $25.1M of capital expenditures, Cytokinetics's free cash flow was -$548.9M over the trailing twelve months, down 34.7% year over year.
- Where does Cytokinetics's cash flow data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
